Turning Point is a precision oncology company with a focus on creating investigational drugs to improve cancer therapies. The company's lead drug candidate, repotrectinib, is a kinase inhibitor that targets non-small cell lung cancer and tumors. The drug is currently being studied in clinical trials and has shown promising results. The company also has a pipeline of other drug candidates, including TPX-0022, TPX-0046, and TPX-0131, which are all in various phases of clinical development.
Turning Point Therapeutics, Inc.'s ticker is TPTX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Turning Point Therapeutics, Inc.
It is https://tptherapeutics.com/
Turning Point Therapeutics, Inc. is in the Healthcare sector
Turning Point Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Turning Point Therapeutics, Inc.'s industry peers: